Physician profile
Hunter Morgan
NPI 1023547221
$5,012.57
in general payments reported to CMS, 2019-2025
22 companies · $935 in 2025
The $935 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $188 · 2021: $453 · 2022: $686 · 2023: $1,612 · 2024: $916 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,332 · Entertainment: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,331.96 |
| Entertainment | $131.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $716.59 | 2022-2025 | Infuse |
| Alcon Vision LLC | $696.01 | 2022-2025 | Dailies, Clareon, Total30 |
| Johnson & Johnson Vision Care, INC. | $568.18 | 2022-2025 | Acuvue |
| Coopervision INC. | $548.83 | 2019-2025 | Myday Contact Lens, Ortho-K Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $256.81 | 2019-2020 | |
| Sight Sciences, INC. | $221.95 | 2023-2024 | Tearcare System |
| Abbvie INC. | $210.19 | 2022-2023 | |
| Lumenis Be INC | $188.34 | 2024 | Optilight |
| Biotissue Holdings INC. | $171.70 | 2022-2025 | |
| Glaukos Corporation | $160.32 | 2021 | |
| Optos, INC. | $159.40 | 2022-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eyevance Pharmaceuticals LLC | $150.00 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $143.22 | 2023 | Eylea |
| Genzyme Corporation | $141.45 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $119.45 | 2024 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $117.65 | 2023 | Dextenza |
| Lkc Technologies, INC. | $106.12 | 2025 | |
| Lombart Brothers, INC. | $103.78 | 2025 | Opd-III |
| Sun Pharmaceutical Industries INC. | $96.67 | 2020-2021 | |
| Horizon Therapeutics Plc | $62.98 | 2021 | |
| Allergan, INC. | $46.72 | 2020-2021 | |
| Amgen INC. | $26.21 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.